PCM
TGTX icon

Penserra Capital Management’s TG Therapeutics TGTX Stock Holding History

Penserra Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
+50,017
New +$2.05M 0.02% 337
2025
Q2 		– Sell
-47,855
Closed -$1.89M – 1132
2025
Q1 		$1.89M Buy
+47,855
New +$1.61M 0.03% 313
2024
Q4 		– Sell
-98,144
Closed -$2.29M – 1195
2024
Q3 		$2.29M Buy
98,144
+73,211
+294% +$1.6M 0.05% 272
2024
Q2 		$444K Buy
+24,933
New +$398K 0.01% 590

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Penserra Capital Management's TGTX Position: Q2 2026 in Review

Penserra Capital Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 50,017 shares worth $2.75M. The stake represents 0.02% of the portfolio and ranks #337 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in TGTX as recently as Q1 2025.

Penserra Capital Management first reported a position in TGTX in Q2 2024 and has held it in 4 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Penserra Capital Management held 50,017 shares of TG Therapeutics worth $2.75M as of Q2 2026.
  • TG Therapeutics was a new Penserra Capital Management position in Q2 2026.
  • TG Therapeutics made up 0.02% of Penserra Capital Management's portfolio in Q2 2026, its #337 holding.
  • Penserra Capital Management first reported a position in TG Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.